175 studies on Mgf curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab indexes 19 published Mgf COA source records from third-party laboratories, covering 8 publicly attributable vendor identities. Across 17 records with positive numeric purity, the arithmetic mean is 99.66%. 0 records report zero purity; these remain in the record count and are excluded from the positive-purity mean. 0 positive purity results are below 90%; 2 records report measured amount more than 10% below the label. The latest recorded test date is 2026-07-06. TitrateLab did not perform these laboratory tests. Source records are not unique batches, and vendor identity does not establish manufacturing role, product safety or overall quality.
As of 2026-10-19, vendor-blind retail asking-price averages for the US delivery market, calculated from the same in-stock exact-strength cells as the Peptide Price Index. Shipping is excluded.
| Strength | Average / vial | Observed range / vial | Average / mg | Coverage |
|---|---|---|---|---|
| 2 mg | $10.50 | $10.50–$10.50 | $5.25 | 1 source · 1 offer |
Asking prices are not manufacturing cost and do not establish product equivalence, quality, safety, or legality. View full price methodology →
All published source records, including absent and zero purity. Matching uses a case-insensitive exact peptide token. No deduplication in the headline; vendor rankings deduplicate eligible certificates separately. The COA archive can use normalized compound names and a different measurement or duplicate policy; totals from these populations need not match.
Latest recorded test: 2026-07-06. Aggregate calculated: 2026-10-19T04:39:09.773699+00:00. Calculation time is not a laboratory observation date.
Within that total, 5 source records have unresolved vendor identity. They remain in corpus-level lab evidence and are excluded from named-vendor rankings.
Eligible vendors have at least 2 deduplicated certificates and 2 classifiable identity observations. Rank uses the 95% lower confidence bound on clean identity results; mean positive purity and certificate count break ties. Missing measurements are not passes. Exact-zero/not-detected and explicit wrong-compound markers count once per adverse certificate. This describes submitted-sample evidence, not every product or shipment, and is not an endorsement.
| Rank | Vendor | Deduplicated certificates | Avg positive purity | Identity adverse results | |
|---|---|---|---|---|---|
| #1 | 4 | 99.72% | 0 of 4 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → | |
| #2 | 4 | 99.72% | 0 of 4 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → |
Vendor identities are included with Pro. Record counts and lab measurements remain visible.
Recent source records: #112030 · #75094 (99.624%) · #84919 (99.648%) · #90666 (99.95%) · #86307 (99.95%) · #15169 (99.491%)
This research significantly advances the potential for **more precise and reliable monitoring of acromegaly disease activity**. By identifying novel biomarkers like **GDNF** and **IGFBP2**, clinicians may eventually h…
Immunogenicity of **Saizen®** (recombinant human growth hormone) was assessed in adult patients with **Growth Hormone Deficiency** (GHD) to understand potential immune responses.
If this study demonstrates that progressive resistance exercise effectively preserves muscle mass and improves physical function during **tirzepatide**-induced weight loss, it could significantly refine clinical guide…
If successful, this trial could establish a **novel pre-conception intervention strategy** for women with overweight or obesity, potentially breaking the intergenerational cycle of adiposity. The inclusion of **Tirzep…
Pilot study aimed to assess a GABA-based supplement's efficacy in **IBS-D** patients, focusing on visceral hypersensitivity and intestinal permeability.
**Optimizing caffeine intake for resistance training could significantly enhance muscle growth and strength gains.** If specific dosing strategies prove superior, individuals could tailor their caffeine regimen to max…
**Clarifying optimal carbohydrate intake for Type 1 Diabetes patients could significantly refine current dietary guidelines**, potentially leading to more stable glycemic control and reduced insulin burden. For indivi…
The BILACO trial aims to identify risk factors for neurocognitive impairment in children with severe cholestasis to optimize liver transplantation timing.
A systematic review investigates the theoretical and scientific basis of peripheral muscle electrostimulation (PMES) to improve cardiac rehabilitation outcomes in elderly patients with sarcopenia.
If successful, this pilot trial could establish **Growth Hormone** as a viable therapeutic option for children with **Phelan McDermid Syndrome**, addressing a critical gap in treatment for this rare genetic form of **…
**Understanding the precise mechanisms and trajectories of early life malnutrition and environmental enteric dysfunction (EED) in mother-infant dyads is critical for developing targeted, effective interventions.** Cur…
This research is critical for **standardizing IGF-1 diagnostics and monitoring**, directly impacting clinicians and patients. By providing assay-specific reference ranges and `SD scores`, it will enable more accurate …
A study aims to determine TV-1106's efficacy on body fat composition in growth hormone-deficient adults over 6 months, compared to placebo.
A Phase 4 study evaluated high-dose **Sandostatin LAR** monotherapy or combination with GH-receptor antagonists/dopamine agonists for biochemical control in acromegaly patients.
**This trial is crucial for establishing evidence-based exercise guidelines for colon cancer prevention, moving beyond observational correlations.** If successful, it could provide the first human data on specific exe…
While specific results are not available in the abstract, this study design explores a highly relevant and practical approach to combating **sarcopenia** in vulnerable populations. **Integrating readily available and …
**Identifying patients at risk for postoperative biochemical discordance is crucial for optimizing acromegaly management and preventing undertreatment.** This study reveals that nearly one-fifth of surgically treated …
A successful Phase 3 trial of Saizen® for Idiopathic Short Stature (ISS) could significantly impact pediatric endocrinology by providing robust evidence for a standardized and effective treatment protocol. For clinici…
If successful, this combination therapy could offer a refined approach for GHD patients with glucose dysregulation. Current GH replacement protocols, while beneficial for body composition, can sometimes worsen insulin…
Understanding the long-term effects of early Oxytocin intervention in Prader-Willi Syndrome (PWS) is crucial for establishing potential disease-modifying therapies. If early Oxytocin treatment demonstrates sustained b…
The continuation of similar monitoring efforts, as seen in the ongoing Increlex® Global Registry (NCT00903110), underscores the importance of continuous post-market surveillance for this patient population.
This large-scale observational study is critical for understanding the true health impact of androgenic anabolic steroid (AAS) use among recreational athletes, a population with alarmingly high prevalence. The finding…
The investigation into recombinant human insulin-like growth factor I (IGF-I) as a treatment for hyperinsulinism is significant due to the limitations of existing therapies. If IGF-I effectively reduces insulin secret…
This study provides promising early evidence that recombinant human growth hormone (rhGH) could be a safe and effective therapeutic option for adolescents grappling with NAFLD. The observed improvements in liver fat, …
If the study demonstrates positive results, it could establish recombinant human growth hormone (rhGH) as a critical and effective treatment for short stature in children with chronic kidney disease prior to transplan…
This study is crucial for strengthening the global fight against doping, particularly concerning growth hormone abuse. By successfully generating standardized, positive control samples, it provides anti-doping laborat…
This study is significant because it could elucidate the precise role of IGF-1 in the pathogenesis of vitiligo, specifically its interaction with oxidative stress. Understanding this mechanism could open new avenues f…
Poor ovarian reserve is a significant and distressing challenge in IVF, often leading to repeated cycle cancellations and emotional burden for patients. The successful completion of this Phase 3 trial suggests a promi…
Despite its termination, this study highlights the ongoing effort to understand and optimize treatments for Primary IGF-1 Deficiency, a condition causing significant growth failure in children. The intent was to gathe…
While the specific, detailed results from this completed Phase 2 clinical trial (NCT01777542) are not included in the provided record, the study's primary objective was to evaluate the efficacy and safety of recombina…
This Phase 2 trial represents a significant step in exploring targeted treatments for Phelan-McDermid Syndrome, a condition with limited therapeutic options. If IGF-1 proves safe and effective in subsequent studies, i…
This study is crucial because it will provide much-needed long-term safety and effectiveness data for Sogroya (somapacitan) in a real-world setting, which is often different from controlled clinical trials. For patien…
This research is crucial because it could lead to a more personalized and tolerable preventative strategy for breast cancer in premenopausal women. By refining the Tamoxifen dose, the study hopes to improve patient ad…
The development of a sustained-release human growth hormone (SR-hGH) formulation could significantly improve treatment adherence and quality of life for children with Idiopathic Short Stature (ISS) by reducing injecti…
The successful completion of this Phase 1 trial is a crucial step towards providing a more convenient treatment option for children with Growth Hormone Deficiency. A long-acting growth hormone like somapacitan could s…
Understanding the acute anabolic and inflammatory effects of testosterone in older men is crucial for optimizing sarcopenia treatments. This research contributes to the knowledge base required to develop safer and mor…
This study successfully focused on the development, implementation, and initial validation of the MAGHD App/MAGHD Framework as a novel self-assessment system for Adult Growth Hormone Deficiency (AGHD) management. The …
This research is significant because it directly addresses a critical unmet need for treatments that can improve connective tissue strength in Ehlers-Danlos Syndrome. If IGF-I proves effective in stimulating collagen …
The concept of continuous subcutaneous hydrocortisone infusion holds significant promise for patients with Addison's Disease, particularly those with co-existing Type 1 Diabetes, by potentially mimicking the body's na…
This pioneering study represents a significant step towards a proactive and personalized approach to sarcopenia management, potentially transforming how this debilitating condition is diagnosed and treated globally. B…
The termination of this trial highlights the significant challenges in developing and testing combination therapies for complex conditions like IGF-1 deficiency and short stature. While this specific study did not yie…
Free, no account — handy when you're working with Mgf.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$14 monthly or $88/year
Create an account